1. Home
  2. GCDT vs CLGN Comparison

GCDT vs CLGN Comparison

Compare GCDT & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GCDT

Green Circle Decarbonize Technology Limited Ordinary Shares

N/A

Current Price

$0.36

Market Cap

5.3M

Sector

Industrials

ML Signal

N/A

Logo CollPlant Biotechnologies Ltd

CLGN

CollPlant Biotechnologies Ltd

HOLD

Current Price

$0.28

Market Cap

5.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GCDT
CLGN
Founded
1992
2004
Country
Hong Kong
Israel
Employees
N/A
39
Industry
Industrial Machinery/Components
Industrial Specialties
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3M
5.2M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
GCDT
CLGN
Price
$0.36
$0.28
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$11.00
AVG Volume (30 Days)
110.4K
22.1K
Earning Date
05-16-2026
05-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$240.45
Revenue Next Year
N/A
$38.03
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.33
$0.27
52 Week High
$5.32
$3.23

Technical Indicators

Market Signals
Indicator
GCDT
CLGN
Relative Strength Index (RSI) 28.79 33.15
Support Level N/A N/A
Resistance Level $0.66 $0.44
Average True Range (ATR) 0.06 0.03
MACD -0.01 -0.00
Stochastic Oscillator 7.00 0.71

Price Performance

Historical Comparison
GCDT
CLGN

About GCDT Green Circle Decarbonize Technology Limited Ordinary Shares

Green Circle Decarbonize Technology Ltd is a company which provides advanced energy saving solutions supported by proprietary phase change thermal energy storage materials and thermal engineering services. As an advocate of decarbonization, the Company designs, develops and provides customized energy saving solutions that bring considerable economic benefits to our clients and reduce carbon emissions for a sustainable future.

About CLGN CollPlant Biotechnologies Ltd

CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.

Share on Social Networks: